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Abstract
Neuregulin-1 (NRG1) signaling through the tyrosine ki-
nase receptors erbB2 and erbB4 is required for cardiac 
morphogenesis, and it plays an essential role in main-
taining the myocardial architecture during adulthood. 
The tyrosine kinase receptor erbB2 was first linked to 
the amplification and overexpression of erbb2  gene in 
a subtype of breast tumor cells, which is indicative of 
highly proliferative cells and likely a poor prognosis fol-
lowing conventional chemotherapy. The development 
of targeted therapies to block the survival of erbB2-
positive cancer cells revealed that impaired NRG1 sig-
naling through erbB2/erbB4 heterodimers combined 
with anthracycline chemotherapy may lead to dilated 
cardiomyopathy in a subpopulation of treated patients. 
The ventricular-specific deletion of either erbb2  or 
erbb4  manifested dilated cardiomyopathy, which is ag-
gravated by the administration of doxorubicin. Based 
on the exacerbated toxicity displayed by the combined 
treatment, it is expected that the relevant pathways 
would be affected in a synergistic manner. This review 
examines the NRG1 activities that were monitored in 
different model systems, focusing on the emerging 
pathways and molecular targets, which may aid in un-
derstanding the acquired dilated cardiomyopathy that 
occurs under the conditions of NRG1-deficient signal-
ing.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: We have reviewed the cardiac requirement 
of neuregulin-1 (NRG1) signaling through the receptor 
tyrosine kinase erbB2/erbB4. The evidence indicates 
that the NRG1/erbB signaling pathway displays a panel 
of activities implicated in maintaining the myocardial 
architecture during remodeling, which may explain why 
the combined treatment with antibodies against erbB2 
and anthracycline chemotherapy may evolve into a 
severe dilated cardiomyopathy. We have further exam-
ined the potential molecular targets, which have been 
either inferred from impaired NRG1 signaling or directly 
assessed by the administration of NRG1. The current 
working hypotheses have been delineated towards a 
prospective molecular understanding of NRG1 signaling 
in heart.
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INTRODUCTION
Dilated cardiomyopathy (DCM) results from the abnor-
mal remodeling of  the myocardium with the eccentric 
growth of  cardiomyocytes in response to valve defects, 
toxic and metabolic causes or gene defects[1,2]. An ac-
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quired form of  DCM is manifested in a subpopulation 
of  breast cancer patients treated with anthracycline che-
motherapy combined with humanized antibodies against 
erbB2. The amplification and over-expression of  erbB2 
occurs in 25% of  all breast cancer types, inducing a high-
ly invasive tumor that has a poor prognosis when treated 
using conventional therapies. Targeted therapies with an-
tibodies against erbB2 were shown to be clinically effec-
tive for erbB2-positive breast cancer patients through an 
objective tumor regression analysis, with lower rates of  
both recurrence and mortality[3]. However, the iatrogenic 
effect of  the combined immunotherapy and chemothera-
py results in increased incidence of  dilated cardiomyopa-
thy, initially affecting a subpopulation of  27% of  treated 
patients[4]. 
We reviewed the panel of  activities of  the NRG1 
pathway that affect cardiomyocyte survival, proliferation, 
differentiation and specification to further focus on the 
synergistically deregulated molecular pathways under the 
experimental conditions of  impaired NRG1 signaling and 
doxorubicin therapy.
THERAPEUTIC CONSIDERATIONS
Evidence from long-term retrospective analyses of  
treatment with the humanized antibodies against erbB2 
(trastuzumab) have suggested that deficient NRG1 signal-
ing sensitizes the heart to anthracycline cardiotoxicity[5,6]. 
These studies prompted the sequential administration of  
immunotherapy after chemotherapy in patients with no 
signs of  cardiotoxicity to reduce the incidence of  cardio-
myopathy. The continuous development of  immunother-
apeutic drugs aimed at improving efficacy in tumor cell 
death have recently provided a novel humanized mono-
clonal antibody against erbB called pertuzumab, which 
prevents erbB receptor dimerization and thus blocks 
the activity of  both erbB2 and erbB4. Currently, there 
are ongoing clinical trials about the safety and efficacy 
of  these immunotherapeutics at escalating doses, when 
used to treat a diverse group of  patients with epithelial-
derived cancers. Thus far, the results from the CLEOPA-
TRA study group indicate the beneficial effect of  the 
combined action of  pertuzumab and trastuzumab with 
docetaxel, which leads to the significantly progression-
free and prolonged survival of  patients with breast cancer 
while having a comparable level of  cardiotoxicity both to 
previous formulations and to placebo with trastuzumab 
and docetaxel[7]. These results prompted the FDA prior-
ity review of  pertuzumab for its approval and release into 
the market in June 2012.
In the light of  the cardiac adverse effects of  the 
therapeutics used to block the survival of  cancer cells, re-
searchers have indicated that drugs, specifically those that 
target signaling pathways or kinase receptors and have 
a broad range of  effects on cancer cells, should also be 
studied for cardiac safety[8]. In this regard, the multidis-
ciplinary workshop of  the Association of  the European 
Society of  Cardiology aimed for a consensus in the man-
agement of  treatments while prioritizing the awareness 
of  anthracycline cardiotoxicity and the development of  
new targeted therapeutics[9].
Interestingly, the design of  an observational trial on 
cardiotoxicity in cancer therapies has included an ad-
ditional evaluation of  cardiac risk incidence by analyzing 
the Single Nucleotide Polymorphism/haplotype varia-
tions in the NRG1/ErbB signaling gene components 
(NCT01173341). In addition to its impact on disease 
management, the results from this trial may contribute to 
the knowledge of  genetic modifiers by identifying poly-
morphisms on the genes of  the NRG1/erbB pathway 
that are associated with disease.
THE COMPONENTS OF THE NRG1 
PATHWAY
Neuregulins are transmembrane proteins of  four isotypes 
(NRG1-4). Neuregulin-1 is classified into at least three 
subgroups (type Ⅰ-Ⅲ) and has approximately 30 iso-
forms as a result of  its synthesis from different promot-
ers and splicing variants[10]. Neuregulins: of  types I and 
II are processed at the membrane by metalloproteinase, 
ADAM17, 19 and are cleaved by α-secretase activity[11]. 
The release rate of  the amino-terminal active domain is 
modulated by protein kinase C (PKC)-delta[12]. The active 
peptide of  the NRG is related to the epidermal growth 
factor (EGF), which contains a cysteine-rich domain that 
binds to and activates the tyrosine kinase receptors erbB4 
and erbB3, which belong to the EGF receptor (erbB1) 
family. The active forms of  erbB2 and erbB3 receptors 
are considered heterodimers because they lack either an 
opened ligand binding domain or tyrosine kinase activ-
ity, respectively, as opposed to the potential function of  
erbB4 receptor homodimers[13]. 
In the heart, the active domain of  NRG1 secreted 
from endothelial cells binds and activates the erbB2/
erbB4 heterodimers expressed in cardiomyocytes (Figure 
1). The NRG1 pathway, which was initially characterized 
as inducing cardiomyocyte differentiation and specifica-
tion, has been identified as inducing a broader panel of  
activities according to the experimental model system and 
the induced heart condition (Table 1).
THE NRG1 INTRACELLULAR SIGNALING 
CASCADE
The erbB-dependent intracellular cascades have been 
extensively studied because of  their important role in 
cancer cells, thereby providing a basis for analyses of  
signaling mechanisms in other cell types. The NRG ac-
tivation of  erbB receptors mediates the auto- and trans-
phosphorylation of  tyrosine residues at the receptor 
intracellular domain. A subgroup of  phosphotyrosine 
residues bind specific adaptor molecules (e.g., Grb, Shc, 
Src, SH3 domain)[14], ultimately inducing intracellular 
pathways, e.g., MAP kinase and PI 3’-kinase cascades, 
PLC γ, the regulation of  the Ca2+-dependent PKC and 
Nuclear Factor of  Activated T cells  activity (Figure 2)[13,15]. 
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A link between NRG1 and focal adhesion kinase (FAK) 
has been observed in proliferative and migrating cells. 
The Ras/MAPK/erk1/2 pathway was required for 
the NRG1-driven myofibrillogenesis in cultured cardio-
myocytes. This activity was mimicked by a constitutively 
active form of  Ras and inhibited by both its dominant 
negative form and the MEK1 inhibitor PD98059[16,17]. 
The NRG1-induced ability of  cardiomyocytes to prolifer-
ate was manifested by its combined administration with 
Insulin-like growth factor I (IGF-I). The NRG1/IGF-I 
induction of  cardiomyocyte DNA synthesis in both ex 
vivo embryonic development and cultured neonatal car-
diomyocytes was prevented by wortmannin, an inhibitor 
of  PI3’-Kinase. Cellular transfection with an adenovirus 
harboring a constitutively active Akt mimicked the pro-
liferative and protective activities, which were inhibited 
by a dominant negative form of  Akt in the presence of  
NRG1/IGF-I (Figure 2)[17].
Alternative pathways may be activated by the cross-
communication of  erbB2 and G protein coupled recep-
tors. Pro-hypertrophic GPCR agonists (e.g., angiotensin 
Ⅱ, endothelin Ⅰ and isoproterenol) have been implicated 
in the transactivation of  EGFR and erbB2, thereby 
inducing hypertrophic and survival stimuli in cardiac 
cells[18,19]. 
ErbB non-phosphorylated interactions
Intracellular signaling also depends on the binding ability 
of  specific non-phosphorylated residues of  erbB recep-
tors to PDZ (postsynaptic density 95, discs large and 
Zonula occludens-1) domain-containing proteins. This 
interaction with PDZ domain proteins is relevant for the 











Figure 1  Endothelium-Cardiac muscle interactions through paracrine neuregulin-1 signaling. Secreted neuregulin-1 from endothelial cells binds to erbB4 in-
ducing auto- and trans-phosphorylation of ErbB2/ErbB4 heterodimers, expressed in cardiomyocytes. NRG-1: Neuregulin-1; PDZ: Postsynaptic density 95, disc large 
and zona occludens-1 homologous protein domain; ADAM: A desintegrin and metallopeptidase; P: Phosphorylated tyrosine.
  Experimental system Monitored response  Intracellular signal Ref.
  Cultured cells  
     NRG1 administration in neonatal cardiomyocytes Sarcomeric F-actin polymerization PI 3’-kinase [16]
Myofibrillogenesis - Growth Ras-Mek-erk1/2 [17]




     NRG1 administration in human ESC Specification of cardiomyocytes of the conduction lineage [45]
  Animal models
     NRG1b injection to ex vivo  developing E12.5 dpc mouse Differentiation of trabeculae [17]
DNA synthesis, Proliferation PI 3’-kinase [17]
     NRG1 administration in mouse with heart failure Improved cardiac performance [40]
     Hypomorphic NRG1 deficiency in E8.5dpc mouse Destabilization of gene regulatory network in the left ventricle Erk1/2 [39]
     Mouse ventricular-erbB2-KO Overt dilation and reduced survival in erbb2 F/- postnatal mouse [31]
     Mouse ventricular-erbB2-KO Dilation with cellular apoptosis [32]
     Mouse ventricular-erbB4-KO Overt ventricular dilation at 3 mo and reduced survival [33]
     Lapatinib inhibition of erbB1/erbB2 in Mouse erbB2-physiologic hypertrophy in pregnancy MEK1/erk1/2 [34]
     Adult ventricular-erbB4-KO Cell division in myocardial infarction [44]
Table 1  Biological effects of neuregulin-1/erbB in embryonic and postnatal cardiomyocytes
Summary of cardiac activities of neuregulin-1 (NRG1)-erbB2/erbB4 signaling inferred from in vitro system and animal model studies. The NRG1 activities, 
-proliferation, myofibrillogenesis, ventricular remodeling, and repair-, were assessed based on the outcomes of the exogenous administration of NRG1 or by 
the complete or partial loss of erbB2/erbB4 signaling. NOS: Nitric oxide synthase; MEK1: Mitogen activated kinase erk kinase 1; ESC: Embryonic stem cells.
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of  PKC and cleaved by the activity of  the tumor necrosis 
factor-alpha converting enzyme and of  γ-secretase at the 
plasma membrane[23]. In the heart, the identified erbB4 
protein in cardiomyocytes is the JMb non-cleavable splice 
variant[24], which may be proteolytically modulated by the 
proteasome system. Three PPXY motifs couple erbB4 
with WW domain proteins, such as Wwox and ubiquitin 
ligases, thereby either modulating the transcriptional ac-
tivity of  the c-terminal domain when translocated into 
the nucleus or promoting the isoform degradation[25]. 
Of  the two cytoplasmic splice variants CYT1 and CYT2, 
CYT1 mediates specific interactions with SH2 and WW 
binding domain proteins (e.g., PI 3’-kinase, ubiquitin li-
gases)[26]. 
Interestingly, erbb4 polymorphisms and splicing vari-
specific location of  erbB proteins in particular membrane 
compartments and for the modulation of  the receptor 
stability and activity[20]. Despite the significance of  PDZ 
domain proteins in the heart (e.g., MAGUK, actinin bind-
ing proteins), there is not yet evidence for the specific 
PDZ-erbB-interacting proteins in cardiomyocytes. The 
erbB4 receptors, which are endocytosis-impaired, are 
also regulated through proteolysis, which is mediated 
by the proteasome system and the alternative transcrip-
tional activity of  the cleavable juxtamembrane isoform 
JMa[21,22]. These mechanisms either drive the erbB4 pro-
tein degradation or induce the nuclear translocation of  
the JMa intracellular domain. As occurs for the release 
of  the NRG1 active peptides, the release of  the erbB4 








































Figure 2  Representation of neuregulin-1-erbB2/erbB4 intracellular signaling cascade. Schematic representation of active ErbB2/ErbB4 heterodimers through 
phosphorylation, which phosphosites are docking sites for intracellular molecules involved in pathways that modulate myocyte biology. Specific non-phosphorylated 
residues interact to PDZ domain proteins. CT: Cytoplasmic tail; KD: Kinase domain; L: Ligand binding site; TM: Transmembrane domain; NRG-1: Neuregulin-1; PIP2: 
Phosphoinositol-2-phosphate; SOS: Son of sevenless; IP3: Inositol triphosphate; AKT: Thymoma viral oncogene homolog 1, a serine/threonine protein kinase; MEK: 
Mitogen activated kinase erk kinase; Shc: Src homology domain containing transforming protein; Shp: Protein tyrosine phosphatase; FAK: Focal adhesion kinase; 
Gab: Binding protein of growth factor bound protein Grb2; P: Phosphorylated tyrosine residues.
WT KO
20 mm
Figure 3  Ventricular specific erbB4-knockout leads to adult dilated cardiomyopathy. Representative image of transverse ventricular sections stained with 
hematoxilin-eosin. Camber dilation is overt in mouse erbB4-KO hearts in the adulthood. WT: Wild type; KO: Knock-out.
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ants of  the erbb4 gene and, more recently, of  Nrg-1 and 
erbb2 have been linked to the pathogenesis of  non-neo-
plastic disorders[27-30]. However, further experimentation 
is still needed to address the regulation and specific func-
tions of  isoforms in cardiovascular, psychiatric, and other 
diseases.
ERBB REQUIREMENT IN POSTNATAL 
AND ADULT HEART
The clinical implication of  the NRG1 signaling in car-
diology results from the increased incidence of  dilated 
cardiomyopathies in a subpopulation of  breast tumor 
patients undergoing the combined administration of  
anthracycline chemotherapy and humanized antibodies 
against erbB2 protein[4]. The cardiac effect of  the anti-
bodies (i.e., trastuzumab, pertuzumab), which are species 
specific and do not cross-react with the mouse protein, 
were experimentally assessed through the ventricular 
cardiomyocyte-specific deletion of  either the Erbb2 or 
the Erbb4 gene in mice. A ventricular-specific mutation in 
either of  these genes caused dilated cardiomyopathy dur-
ing adulthood (Figure 3)[31-33]. These murine models were 
useful for demonstratingthe cardiomyocyte-autonomous 
requirement of  erbB2/erbB4 during the postnatal re-
modeling of  the myocardium. In agreement with the role 
of  the NRG1-erbB2/erbB4 pathway to prevent ventricu-
lar dilation during remodeling, the lapatinib-mediated 
inhibition of  erbB2 phosphorylation in mice resulted in a 
pathological pregnancy-related dilation of  the ventricular 
chambers that occurred without apparent apoptotic cell 
death (Table 1)[34].
The association of  changes in the NRG1/erbB path-
way with disease was also suggested by the downregula-
tion of  both erbB2 and erbB4 expression during the 
pathologic remodeling of  the myocardium in rodents 
under pressure overload and in humans with a failing 
myocardium[35]. However, it is plausible that a differ-
ent isoform than the normally expressed JMb could be 
expressed in the failing myocardium. In this regard, the 
human erbB4 JMa CYT1 isoform manifested a similar 
activity to the endogenous erbB4 JMb isoform in cardiac 
morphogenesis in transgenic mice[36]. A different role 
than the classical activity of  transmembrane tyrosine 
kinase receptor is displayed by the cleavable erbB4 iso-
form, which acts as a transcriptional co-activator or co-
repressor[37]. The nuclear localization of  the full-length 
erbB4 protein has recently been observed in cultured 
adult rat cardiomyocytes under the stress conditions of  
cell isolation, and the protein was suggested to participate 
in DNA damaging processes[38].
Subcellular localization of erbB2/erbB4
Clues about a local cardiomyocyte effect of  NRG1 on 
the maintenance of  the myocardial architecture may arise 
from the subcellular localization of  the receptors. The 
erbB2/erbB4 proteins accumulated within the T-tubule 
membrane system of  cardiomyocytes and the intercalated 
discs (ID) (Figure 4)[33].
























Figure 4  Functional interaction of molecules placed at the T-tubules. The ErbB2 and ErbB4 proteins are localized to the T-tubules. This compartment of the sar-
colemma provides specific sites for functional interactions with molecules at the sarcoplasmic reticulum and at the myofibril Z-band. Molecular interactions at the T-tu-
bules and at the intercalated discs provide the electric-contractile coupling of the myocardium. Scheme of the sarcomeric units of thin and thick filaments are anchored 
by titin and actin at the Z-band via α-actinin scaffold protein complex. Muscle LIM domain protein (MLP), telethonin (T-cap) and PDZ and LIM domain protein (ZASP). 
PDZ: Postsynaptic density 95, disc large and zonula occludens-1; ADAM: A desintegrin and metallopeptidase; SERCA: Sarcoplasmic reticulum calcium ATPase; Plb: 
Phospholamban; RyR: Ryanodine receptor; SR: Sarcoplasmic reticulum.
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T-tubules place membrane molecules in close apposition 
with the myofibril Z-disc, thereby providing a specific 
context for the functional interactions among molecules 
at the plasma membrane, sarcoplasmic reticulum (SR) 
and the myofibril Z-disc. The ID are highly specialized 
Z-disc structures at the cell-cell contact that provide the 
anchorage of  the sarcomeres to the membrane and place 
the connexin-43 gap junctions, assuring electric transmis-
sion and rhythmic contraction of  cardiomyocytes.
Concerning the erbB subcellular context, it is specu-
lated that NRG1 may act on cues at the cytoskeletal 
pathways that are required for myocardial remodeling. A 
connection to the cytoskeleton may be required for the 
feedback modulation of  NRG1 signaling with wall stress 




The in vivo administration of  NRG1, under different 
conditions of  mouse cardiac pathology, contributed to 
the amelioration of  ventricular contraction (e.g., reduced 
left ventricular end systolic dimensions, increased ejec-
tion fraction). In these experiments, the NRG1-mediated 
functional performance of  the ventricular chambers was 
correlated with the increased phosphorylation of  the my-
osin regulatory light chain (RLC) (Table 1)[40]. However, 
the administration of  NRG1 in knockout mice for the 
myosin light chain kinase (Mlck) gene improves cardiac 
function without increasing the phosphorylation level of  
RLC[41], thus implicating additional mechanisms for con-
tractile improvement.
In cultured cardiomyocytes, NRG1 exerts a negative 
inotropic effect through either NOS activity or the ac-
tivation of  the muscarinic response (Table 1)[42,43]. Both 
nitric oxide and active muscarinic receptors modulate the 
inotropic response to beta-adrenergic stimulation, which 
may result in an improved fractional shortening. Indeed, 
there is a general lack of  evidence for either a direct 
NRG1-mediated inotropic effect or an induced change 
in calcium handling or in myofilament calcium sensitivity 
that may provide a molecular explanation for the NRG1-
mediated enhancement of  cardiac systolic function. 
Additional repair activities have been suggested 
through the induced proliferation of  cardiomyocytes 
in a murine model of  cardiac infarction. In this setting, 
NRG-1/erbB4 was shown to induce mononucleated 
cardiomyocytes to proliferate, thereby contributing to the 
cardiac repair mechanisms in one-week-old myocardial 
infarction without affecting the level of  apoptotic cell 
death (Table 1)[44]. This activity is particularly interesting 
for the renewed research of  the cardiomyocytes’ re-entry 
into the cell cycle and the use of  stem cells to re-populate 
the injured myocardium[45-47]. In this regard, pluripotent 
cells may also repair damage myocardial areas through 
the secretion of  relevant growth factors[48]. 
The evidence for the essential role of  NRG1-erbB2/
erbB4 prompted an evaluation of  the safety and efficacy 
of  NRG1 administration in patients with chronic heart 
failure and focal ischemia (Phase I NCT01258387, Phase 
Ⅲ NCT01439893, NCT01541202 trials)[49,50]. The panel 
of  activities displayed upon NRG1 administration has 
been well reviewed[51] and indicates a pleiotropic effect 
on cardiac muscle and vascular cells[51]. The ultimate con-
tribution of  each identified NRG1-mediated activity on 
cardiac performance remains to be defined. Moreover, the 
employment of  NRG1 for the treatment of  cardiac dys-
function still requires a mechanistic understanding of  how 
this signal exerts its effect as well as which critical molecu-
lar targets of  this pathway affect cardiac remodeling.
MECHANISMS OF CARDIOTOXICITY: 
THE ROLE OF NRG1/ERBB SIGNALING
The evidence of  the critical activity of  NRG1 towards 
anthracycline cardiotoxicity led to improvements in the 
clinical management of  administering chemotherapy and 
antibodies against erbB2. Further investigation is required 
to understand the molecular link of  a NRG1 deficiency 
and exacerbated cardiotoxicity. The individual therapies 
with either antibodies against erbB2 or anthracyclines 
exert a cardiotoxic effect at a lower incidence rate com-
pared to the combined treatment. Chemotherapy with 
anthracycline derivatives may result in both immediate 
and delayed cardiomyocyte toxic events. The induction 
of  the oxidative stress response that underlies anthracy-
cline cardiotoxicity has been related to cellular apoptosis 
and necrosis as the mechanism of  toxicity. However, 
employing antioxidants in radiation- or chemotherapy-
treated patients resulted in an unclear improvement in 
cardiac function. These results led to the conclusion that 
oxidative stress may be viewed as a two-way process by 
which radical oxygen species (ROS) mediate tumor cell 
death and promote cell survival through the degradation 
of  anthracyclines[52]. In addition, clinical studies aimed 
to reduce the oxidative and inflammatory process during 
ischemic dilated cardiomyopathy and chronic heart fail-
ure have not yet provided a therapeutic strategy because 
of  dissimilar explanations among the trial results[53]. It is 
therefore likely that ROS-independent mechanisms may 
play a more important role in the doxorubicin-induced 
myocardial damage than previously evaluated[54].
Direct evidence for the role of  NRG1 against an-
thracycline cardiotoxicity was provided by the protective 
activity of  NRG1 against doxorubicin-mediated myofibril 
disarray and in preventing the toxic degradation of  tro-
ponins in cultured cardiomyocytes (Table 2)[55,56]. The car-
dioprotective activity of  NRG1 was also inferred in vivo 
by the doxorubicin-aggravated contractile dysfunction in 
heterozygous NRG1 mutant mice and by the exacerbated 
cardiac chamber dilation in the ventricular-specific erbB4-
knockout mice (Table 2)[57,58]. 
The serum level of  both the cardiac troponins (e.g., 
cTnI) and  brain natriuretic peptide (BNP) are relevant 
markers for the follow-up of  acquired cardiac pathology 
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in trastuzumab- and anthracycline-treated patients[59,60]. 
Indeed, the detection of  the cTnI and BNP serum levels 
was useful for validating the exacerbated cardiotoxicity 
displayed by an injection of  doxorubicin in the ventric-
ular-specific erbB4-knockout mouse. The hypertrophic 
hallmark, i.e., the natriuretic peptide of  the atrial type, was 
expressed at a relatively low level in doxorubicin-treated 
wildtype (WTD) animals and at intermediate levels in 
the doxorubicin-treated erbB4-KO (KOD), compared 
to the robust expression in erbB4-KO[33,58]. The expres-
sion of  BNP was at a similar level in the erbB4-KO and 
in both WTD and KOD mice compared to the wildtype. 
A contrasting finding between WTD and treated KOD 
mice was the differential expression of  both a group of  
genes related to oxidative stress and molecules of  the 
apoptotic-death pathway that underlined the WTD (Table 
3)[58]. The administration of  doxorubicin to erbB4-KO 
mice led to the synergistic deregulation of  the ubiquitin-
proteasome system. The observed downregulation of  
the IGF-I/PI3’-Kinase axis, which may respond to lower 
levels of  PPAR[61] or to a deficient activity of  CREB un-
der the control of  NRG1[62], may represent a potential 
mechanism acting on the deregulation of  the ubiquitin-
proteasome system in erbB4-KOD hearts.
The deregulated group of  genes of  the ubiquitin-pro-
teasome system was characterized by the upregulation of  
ubiquitin-ligase, which induced large protein aggregates 
in cardiomyocytes within the doxorubicin-treated erbB4-
KO. Autophagic vacuolization, which is the recommend-
ed term for the cellular appearance of  large ubiquitin-
positive protein aggregates[63], resulted in a 7-fold increase 
of  affected cardiomyocytes relative to the non-treated 
erbB4-KO (Table 3). The perturbation of  the ubiquitin-
proteasome system induced by a genetic modification in 
mice led to cardiomyocyte necrosis and cardiac chamber 
dilation[64]. Moreover, the level of  protein ubiquitination 
was documented as a useful predictor of  myocardial de-
terioration in patients to follow cardiac transplantation[65]. 
The monitoring of  necrotic cardiomyocytes, by the de-
termination of  the cTnI serum level, is a highly sensitive 
cardiotoxic marker that is employed in the follow-up of  
breast tumor patients undergoing trastuzumab and che-
motherapy[59’60]. 
A search for biomarkers in the early detection of  
doxorubicin cardiotoxicity in both heart and peripheral 
blood mononuclear cells through the determination of  
differential gene expression indicated that the most sig-
nificant group of  genes was represented by changes in 
the canonical NRF2-oxidative stress response pathway, 
protein ubiquitination and the PI3’K/AKT signaling 
pathway[66]. Collectively, these results extend our current 
knowledge by demonstrating that the impaired NRG1 
response in erbB4-KO hearts to doxorubicin toxicity has 
a net result of  the induced autophagic vacuolization of  
cardiomyocytes, which is consistent with the association 
of  abnormal protein homeostasis with a severe cardiac 
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  Experimental system  Monitored response   Ref.
  Cultured cardiomyocytes
     NRG-1 administration Prevented myofibril disarray [55]
Attenuated troponin degradation [56]
  Animal models
     NRG1-deficiency/doxorubicin (NRG1 heterozygous mouse) Induced heart failure  [57]
     NRG1-deficiency/doxorubicin (Ventricular specific-erbB4-KO) Deregulated Protein Homeostasis Autophagic vacuolization   [58]
Table 2  Biological effects of combined neuregulin-1/erbB signaling and anthracyclines
Summary of effects mediated by anthracycline-induced toxicity and by neuregulin-1 (NRG1)-erbB2/erbB4 signaling in in vitro system and animal models. 
The NRG-1 activities on cardiomyocyte survival, myofibril organization and ventricular homeostasis were assessed based on the exogenous administration 
of NRG1 or by the outcome of an impaired signaling as discussed throughout the article.
  Morphology WT KO WTD KOD
  Young adult (1 mo)
     Heart/body 
     weight (mg/g)
   5.2 ± 0.4   5.3 ± 0.6   5.2 ± 0.5    6.2 ± 0.8a 
     Body weight (g)   17.4 ± 2.0 17.3 ± 2.2 17.3 ± 2.0 17.2 ± 1.5
  Adult (3 mo)
     Heart/body 
     weight (mg/g)
   5.6 ± 0.6    7.0 ± 0.8d  5.4 ± 0.7    6.7 ± 0.8d
     Body weight (g)   30.1 ± 2.5 30.3 ± 2.2 29.4 ± 2.2 28.4 ± 2.2
     Cardiotoxic gene 
     groups
     Dilation (ratio) - 3    1.8 2.8
      Hypertrophy 
     (ratio)
-    9.9    3.3 6.5
     Damage (ratio) -    3.7    3.7 3.6
     Cell death/
     necrosis (Ratio)
-    3.0    4.3 3.1
  Measured activity
     Caspase 3 
     (arbitrary units)
    0.25 ± 0.17   0.44 ± 0.17    0.84 ± 0.09a   0.35 ± 0.07
     Autophagic 
     vacuolization (n°)
  0.07 ± 0.1 0.35 ± 0.3   0.2 ± 0.2    2.4 ± 2.1a
      Serum cTnI 
     (mg/mL) 
   0.15 ± 0.1   3.6 ± 1.5   0.7 ± 0.2   14.5 ± 4.2a
     LVDP (mmHg) 109.2 ± 7.1     42 ± 8.2a 94.5 ± 5.5  31.5 ± 5.4a
     Tau ½ 37.4 ± 1.9 38.1 ± 4.9 36.1 ± 3.1 34.6 ± 2.9
Table 3  Cardiac phenotypic modifications
Morphological and biochemical modifications studied in the aggravated 
cardiotoxic condition of the doxorubicin-treated-ventricular specific erbB4-
KO mouse model. Summary of hypertrophic-associated morphological 
changes determined in mouse at the age of 1 and 3 mo, group of differen-
tially expressed genes clustered into a wide-range of cardiotoxic condi-
tions, biochemical activities associated to cell death and of physiological 
systolic and diastolic parameters are represented as discussed in the text. 
aP < 0.05 vs WT, dP < 0.01 vs WT and WTD. WTD: Doxorubicin-treated 
wildtype; KOD: Doxorubicin-treated erbB4-KO; WT: Treated wildtype.
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disorder.
CONCLUSION
The NRG1/erbB pathway is critical for the maintenance 
of  the myocardial structure in the adult heart, and more-
over, impaired NRG1 signaling exacerbates anthracycline-
mediated cardiotoxicity. The accumulated evidence indi-
cates that NRG1 displays a panel of  protective and repair 
activities in the heart during the lifespan of  an individual. 
In this context, an impaired NRG1 signaling sensitizes 
the heart to the toxicity of  anthracycline. There is an 
ongoing search for drugs and immunotherapies that can 
inhibit the erbB receptors implicated in tumorigenesis, 
which may also display an iatrogenic effect in the heart. 
The individual treatment with either anthracycline deriva-
tives or the induced deficiency in the NRG1 pathway 
displayed different gene expression profiles in experi-
mental murine models. The doxorubicin-treated hearts 
were characterized by an oxidative stress response, which 
may induce cardiomyocyte apoptosis. The sensitization 
of  the NRG1-deficient heart to the anthracycline toxicity 
resulted in a potentiated deregulation of  the ubiquitin-
proteasome system, with a net result of  the autophagic 
vacuolization of  cardiomyocytes. 
Altogether, the NRG1 activities that affect the myo-
cardial architecture and homeostasis await a mechanistic 
understanding of  how NRG1 modulates remodeling and 
thereby prevents ventricular dilation. Continuous research 
in this area will provide critical molecules and targets that 
may help in the design of  diagnostic tools and therapeu-
tics. 
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